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There is an urgent need for an improved TB vaccine. Vaccine development is hindered by the lack of
immune correlates and uncertain predictive value of preclinical animal models. As data become available
from human efﬁcacy trials, there is an opportunity to evaluate the predictive value of the criteria used to
select candidate vaccines. Here we review the efﬁcacy in animal models of the MVA85A candidate
vaccine in light of recent human efﬁcacy data and propose reﬁnements to the preclinical models with the
aim of increasing their predictive value for human efﬁcacy.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
There is a clear and urgent need for an effective TB vaccine.
Although recent progress in drug and diagnostic test development
is to be celebrated [1,2] effective vaccination is the only cost-
effective measure to achieve long-term control of any infectious
disease epidemic. There are two main TB vaccine development
strategies currently being pursued, both of which aim to retain the
protective beneﬁts of the currently licensed vaccine, BCG, against
severe disease in childhood. These are the replacement of BCG with
an alternative (more potent and safer) priming vaccine and/or by
delivering a booster vaccine months or even years after BCG [3].
The ﬁrst step in TB vaccine development involves preclinical
animal testing in a variety of different species and models. These
models are used to evaluate safety, immunogenicity and efﬁcacy.
The demonstration of safety in a toxicology study conducted in a
relevant animal model is an essential pre-requisite for progressing
to clinical testing. The immunological evaluation of new vaccine(H. McShane), ann.rawkins@
r Ltd. Open access under CC BY-NC-Ncandidates is typically conducted in mice, but with increasing
availability of immunological reagents, can also be conducted in
other species [4e7]. These immunogenicity data are used to opti-
mise vaccine regimes and doses prior to the evaluation of protec-
tion in Mycobacterium tuberculosis challenge experiments. It is the
demonstration of protection in these challenge experiments that
determines which vaccines progress to clinical evaluation. What
protection actually means in these models is an improvement in a
disease e related readout, be it bacterial load (expressed as colony
forming units or CFU) at a ﬁxed time point post challenge, long-
term survival, or pathology score, compared with BCG. It is usual
and preferable for protection in more than one animal species to be
demonstrated before vaccines advance to clinical testing. The ﬁrst
step in clinical testing involves phase I safety studies, which
progress to larger safety and immunogenicity testing in the target
population, within TB endemic countries. If successful, these
studies then lead into efﬁcacy testing in signiﬁcantly larger
numbers of subjects. Such efﬁcacy trials are huge and costly due to
TB incidence rates not being very high, even in the highest burden
settings. There is a ﬁnite capacity to conduct and to fund such ef-
ﬁcacy trials and it is important that data from efﬁcacy trials, when
available, are used to review the predictive value of the criteria used
to progress candidate vaccines. We can then reﬁne, where needed,
the models we use to select which candidate vaccines progress.
Protection in preclinical animal models, together with safety
and immunogenicity in phase I/IIa clinical trials, are the three main
criteria used to select which candidate vaccines should progress toD license.
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lection process include feasibility, standardisation and cost of
manufacturing, potential cost of ﬁnal product, product characteri-
sation, target product proﬁle, regulatory, business and potential
health impact [8]. In the animal models, BCG is used as a ‘gold
standard’ control vaccine, which confers a 1-3 log reduction in CFU
counts (variable between models), or a signiﬁcant degree of
improvement in survival or pathology score. A candidate vaccine,
whether it is a booster vaccine designed to enhance the effects of
BCG, or a new whole mycobacterial vaccine, designed to replace
BCG, should confer an improvement in ‘protection’, i.e an
improvement in the relevant readout for the study, compared with
this BCG alone control group. With almost all of the candidate
vaccines currently being evaluated in clinical trials, this improve-
ment is an additional 0.5e1 log reduction in CFU counts. To date,
there has only been one candidate vaccine that has demonstrated
sterilising immunity in any animal model; this is a recombinant
strain of Mycobacterium smegmatis expressing the ESX secretion
system from M. tuberculosis [9]. This sterilising immunity was
demonstrated in the murine model, although not in all organs nor
in all of the mice. To date, testing of this vaccine has not been re-
ported in any other species but a reduction of bacterial load to
undetectable levels is extremely rare in the mouse model. These
data suggest that it is at least possible to develop vaccines that are
much more effective at reducing bacterial load than the current
generation of vaccine candidates. We do not yet know what the
effect of such enhanced protection in preclinical models will be on
clinical efﬁcacy, but evidence that sterilising immunity is achiev-
able, suggests that the bar for what is considered ‘effective’ in an-
imal models should perhaps be raised.
Human efﬁcacy trials are currently powered to demonstrate at
least a 60% improvement in efﬁcacy over BCG alone. This is a high
bar, which is driven mainly by logistics and the cost of efﬁcacy
testing. We now have the results of the ﬁrst phase IIb trial in infants
with the most clinically advanced candidate TB vaccine, MVA85A,
which did not demonstrate any signiﬁcant improvement in pro-
tection over BCG alone in BCG-vaccinated infants in South Africa
[10]. This trial was powered to show a 60% improvement over BCG
alone and vaccine efﬁcacy was not statistically signiﬁcant at 17.3%
(95% CI-31.9e48.2). In this article, we review the preclinical efﬁcacy
data for MVA85A in the context of this human efﬁcacy study, and
consider the implications for preclinical animal testing. It is
essential that as a ﬁeld, we maximise the value of this and subse-
quent efﬁcacy trials with other candidate vaccines by considering
whether reﬁnements to our vaccine selection criteria are now
merited. It is hoped that in this iterative way, we will gradually
understandmore about what thesemodels can tell us and how best
to utilise them.
2. Review of preclinical data with MVA85A
MVA85A is a recombinant strain of Modiﬁed Vaccinia virus
Ankara expressing the conserved mycobacterial antigen 85A [11]
and is designed to boost the effects of BCG. The protective efﬁ-
cacy of a BCG prime eMVA85A boost regime has been evaluated in
four animal models: mice, guinea pigs, non-human primates and
cattle. In mice, boosting BCG administered intranasally (i.n.) with
MVA85A, also administered intranasally, increased the level of
protection seen compared to i.n BCG alone [12]. Interestingly, in
this study, boosting i.n BCG with i.n BCG also improved protection
compared to a single BCG i.n. The level of reduction in bacterial load
seen when boosting with MVA85A or BCG was comparable, and
was approximately a 2 log10 CFU reduction in the lungs. Boosting
BCGwith MVA85A administered systemically did improve the level
of protection seen in the spleen, but not in the lungs. In a guinea pighigh dose challenge experiment, BCG boosted with MVA85A and
then a second viral vector, a recombinant fowlpox also expressing
antigen 85A, led to a statistically signiﬁcant improvement in sur-
vival compared to BCG alone [13]. A previous study with a ﬁxed end
point and a lower challenge dose did not distinguish between BCG
and BCG e MVA85A [14] and interestingly, BCG boosted with BCG
did not enhance protection over a single BCG immunisation. Two
separate studies have been conducted evaluating the protective
efﬁcacy of a BCG prime e MVA85A boost regime in non-human
primates. The ﬁrst demonstrated a trend towards improved con-
trol in comparison to BCG alone, but none of the parameters
reached statistical signiﬁcance [15]. There was an approximately
0.5 log10 reduction in CFU counts in the lungs in the BCGeMVA85A
group compared to the BCG group. The second non-human primate
experiment, which utilised for the ﬁrst time an aerosol route of
M. tuberculosis challenge, did not demonstrate either a signiﬁcant
effect of BCG or any difference between BCG and BCG eMVA85A in
terms of survival, a much more stringent read-out with low sta-
tistical power [16]. The only read-out which demonstrated a pro-
tective effect of vaccination in this study was a signiﬁcant reduction
in overall pulmonary disease burden, and an equivalent effect was
seen in both BCG and BCG-MVA85A vaccinated animals. In cattle,
challengedwithMycobacterium bovis, thereweremore disease-free
animals in a group vaccinated with BCG and then boosted with
MVA85A (n ¼ 4/10), than there were in a BCG alone group (n ¼ 1/
10), or in a naïve group (n ¼ 0/10) [17]. Only the BCG e MVA85A v
naïve group comparison was statistically signiﬁcant in this exper-
iment. Overall, the BCG-MVA85A vaccination resulted in statisti-
cally signiﬁcant reduction in pathology in four/eight parameters, an
improvement over BCG which reduced pathology signiﬁcantly in
only one parameter.
This preclinical work demonstrated that MVA85A can improve
BCG induced protection in these animal models. However, this
enhanced protection has not been seen in every challenge experi-
ment conducted. Furthermore the level of improvement seen in
most of these experiments was relatively modest, and was usually a
reduction in bacterial burden rather than sterilising immunity.
Prior to obtaining human efﬁcacy data, it was not clear what this
modest level of improvement or efﬁcacy meant in terms of pre-
dicting efﬁcacy in humans. It is now clear that this variable and
modest level of preclinical efﬁcacy does not predict efﬁcacy in BCG-
vaccinated infants, at least at the substantial level required in
humans for vaccine development to be progressed. What is still
unclear is the magnitude of improvement in animal models which
is needed in order to predict the substantial level of improvement
in protection required in humans and further clinical efﬁcacy data
on vaccine candidates with different pre-clinical packages are
needed. Vaccine candidates demonstrating consistent and robust
high level efﬁcacy across a range of animal models might be more
likely to succeed in human efﬁcacy testing. A key issue is how we
can use the information derived from the preclinical and clinical
efﬁcacy with MVA85A to review and reﬁne where necessary the
models used for the selection of candidate vaccines for subsequent
efﬁcacy testing.
3. Review of design of preclinical animal model experiments
Over the past decade, progress in TB vaccine R&D has resulted in
large numbers of antigens, adjuvants, antigen delivery systems, etc
being proposed as potential candidates for an improved TB vaccine.
In the absence of a surrogate marker of protection, all of these
candidates have needed to be tested for efﬁcacy in animals. This
high demand has driven animal study designs which can provide
data over a relatively short time scale and, for ethical reasons, to use
theminimum number of animals to achieve a clear result. There are
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and animal models which are important to consider. The animal
models per se are different compared with humans, in terms of
disease manifestation and the immune response to vaccination or
infection, with the responses in humans being considerably more
variable than experimental animals [18,19]. Many clinically relevant
factors are not taken into account in the laboratory setting, such as
the strains of M. tuberculosis used in challenge experiments which
are typically standardised laboratory strains rather than clinical
isolates; and the nature of exposure to infection, in terms of fre-
quency and dose. Furthermore, the deﬁnition of ‘protection’ is
different in the animal models and human efﬁcacy trials.
3.1. Species differences
There are many species differences which could inﬂuence the
ability of animal models to predict outcomes in humans. There is an
important role in vaccine development for animal species which
more closely resemble humans e.g. macaques because they most
closely resemble the human response to vaccination and infection.
Ethical and ﬁnancial constraints prevent these more complex
models being used as a routine selection tool to narrow down the
multiple choices for vaccine development. It is therefore more
useful to reserve macaque experiments for vaccines which have
already been shown to be effective in smaller animal models. These
experiments allow investigations which bridge between animal
and human studies, such as identiﬁcation or veriﬁcation of corre-
lates of protective immunity which can then be used in the more
tractable animal species to make them more relevant to humans.
In the MVA85A trial, one key difference between the animal
models and the humans was the age of the subjects. Whereas all of
the animal models were conducted in adult animals, the efﬁcacy
trial was conducted in infants. Studies of immunogenicity in
neonatal animal models are possible and are being conducted [20].
Immunogenicity studies have the potential to identify fundamental
differences between the adult and infant immune responses,
particularly if conducted in non-human primates. Without an im-
mune correlate of protection, the immunogenicity data needs to be
supported by protection studies, but infection of very young ani-
mals with M. tuberculosis is difﬁcult from both a technical and
ethical perspective. Studies where the M. tuberculosis challenge is
delayed until the animal is moremature are valuable and have been
used, for example to study the duration of BCG-induced protection
in cattle [21].
Infants are not the only target population for many of the
candidate vaccines in development and data from efﬁcacy trials in
adults may yet provide important clues about the most predictive
animal species for humans. In recent years, there has been
increasing recognition of the importance of adolescents and young
adults as a target population, in part because this age group is
responsible for mostM. tuberculosis transmission. The next planned
efﬁcacy trial with a candidate TB vaccine will be conducted in
adults [22]. It may therefore be premature to place too much
emphasis on neonates at the pre-clinical stage.
3.2. Clinical trial settings
There are many variables in a clinical trial setting that are
controlled for in the laboratory, including diet, exposure to other
pathogens including environmental mycobacteria and helminths,
and inherent genetic susceptibility. Although it may be possible to
incorporate some of these variables into the animal models, in each
clinical trial setting, a different set of parameters will apply and the
value of doing this may be questionable. Furthermore, increasing
the complexity of the preclinical models may impact on thereproducibility of the results and reduce the value of efﬁcacy
testing in animals. However, by understanding the key differences,
there is an opportunity to improve the models.
3.3. M. tuberculosis strain and exposure
One clear difference between the animal challenge experiments
and a human efﬁcacy trial is the means by which individuals
become infected. In the animal models, animals are exposed to a
relatively high dose, single exposure to a laboratory-adapted strain
of M. tuberculosis. There are few data on the impact of novel vac-
cines against clinically relevant strains of M. tuberculosis [23e26].
One important question is whether challenging animals with
relevant clinical isolates would improve the predictive value of
these models, and more data on comparative efﬁcacy against lab-
oratory and clinical strains are needed. A systematic evaluation of
the efﬁcacy of different vaccine types againstM. tuberculosis strains
from endemic regions would be extremely useful. Such information
would enable a selection of M. tuberculosis strains to be used
alongside, or potentially in place of the laboratory strains.
Once a more appropriate challenge strain(s) has been selected,
consideration should also be given to the means by which animals
are infected. A variety of challenge routes are used across the ani-
mal models, with inoculation via the respiratory mucosa being
widely regarded as the most relevant for human vaccine develop-
ment. A fundamental difference between ﬁeld efﬁcacy trials and
laboratory animal exposure is the number of exposures. It is highly
likely that a human infection develops after multiple exposures,
probably containing only a few organisms [27]. Infection may be
established after one or several exposures and may not occur even
after multiple exposures. In contrast, inoculation of experimental
animals is a single high dose exposure (via aerosol, nasal or trachea-
bronchial delivery) because the study design requires all animals to
be infected, in order to keep the number of animals per-group to a
minimum. This results in an unnatural ‘challenge’ to the vaccine-
induced immune response and it is likely that the initial hoste
pathogen interactions are quite different in humans and experi-
mental animals. The natural exposure system developed by Nardell
and colleagues addresses several of these issues [28]. In this model,
guinea pigs breathe the extracted air from award of TB patients and
thereby receive multiple, low-dose aerosol exposures to clinical
strains. Vaccine efﬁcacy studies in these naturally exposed guinea
pigs are planned and will allow a comparative assessment of the
response of a vaccinated animal to natural vs experimental infec-
tion and this information can then be used to improve the exper-
imental infection systems.
3.4. Magnitude of vaccine efﬁcacy
There is a further discrepancy in terms of the magnitude of
vaccine efﬁcacy which clinical and preclinical studies are powered
to detect. The MVA85A efﬁcacy trial was powered to detect a 60%
improvement over BCG alone [10]. In animal models, the magni-
tude of improvement upon BCG by candidate vaccines evaluated to
date is generally modest and such small increases in efﬁcacy would
not be detected in a clinical trial. If we consider a 60% improvement
in clinical efﬁcacy a minimum level for progressing a vaccine
through to licensure, we should expect the endpoints in the pre-
clinical animal studies to be capable of detecting a similar magni-
tude of improvement and to be suitably powered.
3.5. Deﬁnition of protection
It is important to recognise the different deﬁnitions of protec-
tion in humans and animal models. In animal models, efﬁcacy is
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compared to control groups as measured by disease-related pa-
rameters e.g. bacterial load in lungs and or spleen, severity of pa-
thology, time to death. Often in these studies, a vaccine is regarded
as providing protection even if there are measurable bacteria/pa-
thology in the organs, and even if some animals do not survive. The
equivalent in a human efﬁcacy trial would be a reduction in severe
disease but, for ethical reasons there is never an opportunity for
severe disease to develop because of active follow-up. Therefore, in
humans, efﬁcacy is deﬁned as the prevention of TB disease using
clinical endpoints and any individual who meets this disease
endpoint deﬁnition is not protected. As mentioned above, some
vaccination protocols (including MVA85A [17],) are capable of
inducing a sterilising or disease-free effect in animals but this level
of protection is rare, and is not considered essential for vaccine
selection. Thus, the majority of the pre-clinical evidence for pro-
tection is based upon a relative reduction in organ CFU or
pathology.
There has been much debate over the merits of measuring ef-
ﬁcacy at early or late time points post-challenge because some
vaccine candidates have a more pronounced effect at the later
stages [24,29]. However, whether it is soon after infection, or in the
later stages, the effect being demonstrated is usually a partial
clearance of bacteria or reduced inﬂammation/tissue damage. Even
though this indicates the potential of the vaccine to induce an
effective anti-mycobacterial immune response, we do not under-
stand themeaning of e.g. a 0.5e1.0 log reduction in bacterial load in
animals in terms of human disease prevention. Survival studies,
where vaccines are compared in terms of preventing animals
reaching severe disease end-points, have the potential to measure
disease prevention. However, in all reported survival studies to
date, the effect of the candidate vaccine has not been prevention of
disease but merely a slowing of disease progression such that
survival of vaccinated animals is prolonged compared to controls.
Until there are sufﬁcient human efﬁcacy data with which to
correlate a particular parameter in animal models, it might bemore
useful to design the animal efﬁcacy studies with a greater emphasis
on the efﬁcacy end point of the clinical trial, which is likely to be
absence of disease, not simply a reduction in disease burden.
3.6. M. tuberculosis infection as an endpoint
Now is the time to consider a fundamental change from reduc-
tion of disease to prevention of disease as the end-point. A potential
step even further is to consider establishing animal models to
demonstrate protection against M. tuberculosis infection, rather
than TB disease. This is of relevance to human vaccine testing as
prevention of M. tuberculosis infection has been suggested as a
more feasible endpoint in a human efﬁcacy trial, allowing smaller
and shorter efﬁcacy trials. However such a preclinical model would
be very difﬁcult to develop as the currently available tools to deﬁne
infection in humans are not directly transferable to most of the
animal models.
Study designs which measure prevention of disease would
require large group sizes because presence or absence of infection
is a binary endpoint. A time to event analysis would increase the
power but the group sizes would still be signiﬁcantly larger than
those currently used in animal challenge experiments. A clear and
reliable biomarker which reﬂects exposure is also needed. Current
immune markers measure the induction of an adaptive immune
response but do not predict outcome. Biomarkers of an innate
immune response to infectionwould be extremely useful andmuch
progress has been made in recent years with several potential
biomarkers being identiﬁed [30e32]. Validation of these in the
animal species is feasible and quantitative, and thus robust andreproducible assays could be developed. The assay would ideally be
performed repeatedly on the same animal to permit time-course
analysis but, because the site of infection is the lung, these assays
might be more accurate and reliable when performed on lung tis-
sue, at a single time point. Clinical chemistrymarkers, lung imaging
and metabolic markers might also help because they would
improve the accuracy with which to deﬁne disease or not. Non-
human primates (NHPs) are the most suited animal models to
perform such analyses because of a direct translation to the clinic
but it will never be feasible to perform clinical trial scale studies in
NHP. However NHP are invaluable for the validation of biomarkers
and to establish assays which bridge pre-clinical and clinical
studies, enabling development of improved small animal models.
BCG remains the benchmark against which the new endpoints
would need to be set.
These novel pre-clinical study designs will involve larger
numbers of animals and perhaps a tiered approach to efﬁcacy
testing is required, with this level of efﬁcacy screening reserved
only for the most promising vaccine candidates. Immunological
evaluation will become an increasingly important criterion in
vaccine selection, and the need for a correlate of protection be-
comes even more pressing. Attempts to associate various measures
of cell-mediated immunity with risk of disease have to date failed
to reveal a clear correlate [33]. In other diseases, functional immune
responses such as virus neutralisation or serum bactericidal assays
serve as reliable correlates of protection and recent reports of a
more functional mycobacterial growth inhibition assay suggests
that such assays may be a more useful in-vitro tool than more
conventional measures of cellular immunity [34]. We will only be
able to identify vaccine-induced correlates of protection once we
have an effective vaccine. However in the meantime, work on
identifying correlates of risk will generate potential correlates for
validation in efﬁcacy trials.
The above discussion only addresses efﬁcacy screening in the
context of primary infection. Post-exposure vaccines are being
developed and these have been evaluated in animal models for
their ability to prevent disease reactivation [29]. Whether any of
these complex models predict efﬁcacy in humans remains to be
proven. The factors and variables which trigger reactivation of
latent M. tuberculosis infection in humans are not possible to
reproduce in an animal model, but mouse models involving relapse
following incomplete chemotherapy have proven useful as a
screening tool to prioritise candidates. The clinical distinction be-
tween latent infection and disease does not exist in animals, other
than NHPs, but again the value of NHPs is the power to perform
highly relevant in-depth analyses of advanced vaccine candidates
with the information used to improve ﬁrst-line screeningmodels. A
clear and accepted (re-)deﬁnition of protection in the context of
primary infection will certainly help to improve animal models of
latency.
4. Conclusions
Eleven years ago, there were no new TB vaccine candidates
being tested in clinical trials. Animal studies have enabled priori-
tisation of candidate TB vaccines in the absence of a correlate of
protection and substantial progress has been made on the strength
of animal data. However, there was no benchmark for improved
protection over BCG in humans, with which to validate the animal
models. Recent human efﬁcacy data on MVA85A demonstrate that
the modest ‘protection’ observed in preclinical animal models did
not predict the substantial efﬁcacy required in humans. The
increasing number of vaccines reaching clinical testing is to be
welcomed, as it is only by moving different candidate vaccines into
clinical testing that we will achieve the goal of developing an
Table 1
Recommendations for improving preclinical evaluation.
 Testing with clinical Mtb isolates
 Powering preclinical studies for the same level of efﬁcacy as desired in human
clinical trials
 Preclinical studies conducted in same age group, neonates or adults, as target
for human vaccine trials
 Robust models of low dose, repeated exposure are developed
 Markers of infection are developed with which infection models can be
established
 Better models for BCG boosting vaccines and latency
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currently in the clinical pipeline has a pre-clinical data package that
is markedly different from MVA85A. It is therefore important to
consider the implications of the MVA85A efﬁcacy trial for these
other candidates and more broadly for preclinical models of TB
vaccine development. A comparison of the animal and human data
for MVA85A suggests that the animal studies will be more pre-
dictive if the study designs are optimised tomore closely reﬂect the
targeted effect of the vaccine in the clinical trial. Parameters to be
considered include the subjects (species, age), the strains and dose
of M. tuberculosis and most importantly, the end-point which will
be used to deﬁne efﬁcacy, which then allows the study to be
powered appropriately. Subsequent trials with other candidates in
other target populations will provide valuable new information
with which we can further reﬁne the animal models. We can only
‘validate’ these preclinical models once we have a new vaccine
which is effective in humans. Until then we should continue to
iteratively reﬁne the models, as clinical efﬁcacy data becomes
available, the predictive value of which will then be evaluated again
in human efﬁcacy trials.
Standardised, head-to-head screening of vaccine candidates in
independent laboratories has evolved as an important feature of
the global TB vaccine effort, and this must be maintained [14,15].
Furthermore, key preclinical challenge experiments should be
repeated to ensure reproducibility, before committing to large,
expensive efﬁcacy trials. Animal data are pivotal in the under-
standing of vaccine induced immune responses and identiﬁcation
of correlates of protection. As reﬁned algorithms for vaccine iden-
tiﬁcation and selection emerge, it is imperative that these are
shared and incorporated in a consistent manner.
Table 1 summarises some of the most important elements of an
improved strategy for vaccine selection. The current TB vaccine
portfolio contains more vaccines than it is possible to test in human
efﬁcacy trials and ﬁnancial and ethical drivers will dictate the
number of vaccines we can progress. It is imperative that as a ﬁeld,
we agree upon objective criteria based on accurate, predictive pre-
clinical models so that we have the conﬁdence to select candidate
vaccines for efﬁcacy testing and only advance the vaccines which
are most likely to succeed.
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